CD274 and esophageal adenocarcinoma: Several clinical trials have been completed to explore the therapeutic effect of anti‐PD‐1/PD‐L1 plus nCRT for locally advanced EC: PALACE‐1 trial for ESCC, PERFECT trial for esophageal adenocarcinoma.12, 13